Vladimir Skljarevski

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Pituitary apoplexy in the setting of coronary angiography
    Vladimir Skljarevski
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Neuroimaging 13:276-9. 2003
  2. doi request reprint Efficacy and safety of duloxetine in patients with chronic low back pain
    Vladimir Skljarevski
    Lilly Research Laboratories, Indianapolis, IN, USA
    Spine (Phila Pa 1976) 35:E578-85. 2010
  3. doi request reprint Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain
    Vladimir Skljarevski
    Eli Lilly and Company, Indianapolis, Indiana, USA
    Diabetes Metab Res Rev 25:623-31. 2009
  4. doi request reprint A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain
    V Skljarevski
    Lilly Research Laboratories, Indianapolis, IN, USA
    Eur J Neurol 16:1041-8. 2009
  5. ncbi request reprint Impact of diabetes on vasculature: focus on nervous system
    Vladimir Skljarevski
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Curr Diabetes Rev 1:245-53. 2005
  6. ncbi request reprint Diabetic neuropathies
    Vladimir Skljarevski
    Lilly Research Laboratories, Indianapolis, Ind, USA
    Arch Neurol 63:1502-4. 2006
  7. doi request reprint Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study
    Vladimir Skljarevski
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Pain Med 11:648-57. 2010
  8. doi request reprint A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee
    Amy S Chappell
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Pain Pract 11:33-41. 2011
  9. doi request reprint Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial
    Amy S Chappell
    Lilly Research Laboratories, Indianapolis, IN, USA
    Pain 146:253-60. 2009
  10. doi request reprint Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial
    Vladimir Skljarevski
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    J Pain 11:1282-90. 2010

Detail Information

Publications14

  1. ncbi request reprint Pituitary apoplexy in the setting of coronary angiography
    Vladimir Skljarevski
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Neuroimaging 13:276-9. 2003
    ..PA in the absence of adenoma was confirmed on autopsy. The authors hypothesize that apoplexy here was related to the administration of Omnipaque in combination with the anticoagulation effect of heparin...
  2. doi request reprint Efficacy and safety of duloxetine in patients with chronic low back pain
    Vladimir Skljarevski
    Lilly Research Laboratories, Indianapolis, IN, USA
    Spine (Phila Pa 1976) 35:E578-85. 2010
    ..This was a randomized, double-blind, placebo-controlled clinical trial...
  3. doi request reprint Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain
    Vladimir Skljarevski
    Eli Lilly and Company, Indianapolis, Indiana, USA
    Diabetes Metab Res Rev 25:623-31. 2009
    ..To evaluate the maintenance of effect of duloxetine 60 mg QD over 26 weeks in patients with diabetic peripheral neuropathic pain (DPNP)...
  4. doi request reprint A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain
    V Skljarevski
    Lilly Research Laboratories, Indianapolis, IN, USA
    Eur J Neurol 16:1041-8. 2009
    ..Duloxetine has demonstrated analgesic effect in chronic pain states. This study assesses the efficacy of duloxetine in chronic low back pain (CLBP)...
  5. ncbi request reprint Impact of diabetes on vasculature: focus on nervous system
    Vladimir Skljarevski
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Curr Diabetes Rev 1:245-53. 2005
    ..In addition, the article draws a parallel between microvascular dysfunction observed in persons with overt diabetes and those at risk for it...
  6. ncbi request reprint Diabetic neuropathies
    Vladimir Skljarevski
    Lilly Research Laboratories, Indianapolis, Ind, USA
    Arch Neurol 63:1502-4. 2006
  7. doi request reprint Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study
    Vladimir Skljarevski
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Pain Med 11:648-57. 2010
    ..To assess the maintenance of the effect of duloxetine in the treatment of chronic low back pain...
  8. doi request reprint A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee
    Amy S Chappell
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Pain Pract 11:33-41. 2011
    ..To evaluate the efficacy and safety of duloxetine in the treatment of chronic pain due to osteoarthritis of the knee...
  9. doi request reprint Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial
    Amy S Chappell
    Lilly Research Laboratories, Indianapolis, IN, USA
    Pain 146:253-60. 2009
    ..Adverse-event rates did not differ significantly between treatment groups (49.5% for duloxetine 60-120 mg/day, and 40.8% for placebo)...
  10. doi request reprint Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial
    Vladimir Skljarevski
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    J Pain 11:1282-90. 2010
    ..2%) than patients in the placebo group (5.4%) discontinued because of adverse events (P = .002). Nausea and dry mouth were the most common treatment-emergent adverse events with rates significantly higher in duloxetine-treated patients...
  11. pmc A closer look at the baseline-observation-carried-forward (BOCF)
    Hong Liu-Seifert
    Lilly Research Laboratories, Indianapolis, IN, USA
    Patient Prefer Adherence 4:11-6. 2010
    ..We examined modifications of this approach, taking into consideration treatment-related and nontreatment-related reasons for discontinuation...
  12. pmc Efficacy and Safety of Duloxetine in Patients with Chronic Low Back Pain Who Used versus Did Not Use Concomitant Nonsteroidal Anti-Inflammatory Drugs or Acetaminophen: A Post Hoc Pooled Analysis of 2 Randomized, Placebo-Controlled Trials
    Vladimir Skljarevski
    Lilly Research Laboratories, Eli Lilly and Company, Drop Code 1542, Indianapolis, IN 46285, USA
    Pain Res Treat 2012:296710. 2012
    ..31) suggesting no substantial evidence of differential efficacy for duloxetine over placebo on pain reduction or improvement in physical function between concomitant NSAID/APAP users and non-users...
  13. ncbi request reprint Correlation of vibratory quantitative sensory testing and nerve conduction studies in patients with diabetes
    John C Kincaid
    Department of Neurology, Indiana University, Indianapolis, Indiana, USA
    Muscle Nerve 36:821-7. 2007
    ..189 to 0.480 (Pearson correlation coefficients, P < 0.001). The low to moderate correlation between QST and NCS suggests that these tests cannot replace each other but are complementary...
  14. ncbi request reprint Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials
    Solomon Tesfaye
    Diabetes Research Unit, Royal Hallamshire Hospital, Q Floor, Room 26, Glossop Road, Sheffield S102JF, UK
    Diabetes Care 30:2626-32. 2007
    ....